SCHEDULE: FMR LLC Discloses 7.2% Stake in Moderna

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a 7.2% beneficial ownership stake in Moderna Inc. as of December 31, 2025.

Summary

• FMR LLC, a parent holding company, and Abigail P. Johnson, an individual, jointly reported beneficial ownership of 27,961,310.82 shares of Moderna Inc. common stock.
• This aggregate amount represents 7.2% of Moderna Inc.'s outstanding common stock.
• FMR LLC holds sole voting power over 27,860,919.77 shares and sole dispositive power over 27,961,310.82 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is deemed to have sole dispositive power over the same 27,961,310.82 shares, but no sole or shared voting power.
• Subsidiaries of FMR LLC, including Fidelity Management & Research Company LLC, FIAM LLC, Fidelity Management Trust Company, and Strategic Advisers LLC, are identified as entities beneficially owning shares, with Fidelity Management & Research Company LLC owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as a significant stake by a reputable institutional investor like FMR LLC typically signals confidence in the issuer's long-term value and prospects.

Positives

• A significant 7.2% stake by a major institutional investor like FMR LLC (Fidelity) can be interpreted as a vote of confidence in Moderna's long-term prospects and strategic direction.
• The transparency of this Schedule 13G filing provides clear insight into a substantial institutional holding, which can reassure other investors.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Moderna Inc. or the reporting persons regarding Moderna's future performance.

Industry Context

StockSavvy.ai notes that a significant stake by a major asset manager like FMR LLC (Fidelity) often signals long-term conviction in the company's prospects, especially in the biotechnology sector where innovation, pipeline development, and market penetration are key drivers. Such institutional backing can enhance investor confidence in Moderna's strategic direction and market position.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional ownership levels for biotech companies like Moderna are typically high, reflecting the specialized nature of the industry and the reliance on institutional capital.
• A 7.2% stake by a single entity like FMR LLC is a substantial position, comparable to significant holdings seen in other large-cap biotech firms by major asset managers such as BlackRock or Vanguard, indicating a strong belief in the company's long-term value.

Stakeholder Impact

• Shareholders benefit from increased transparency regarding significant institutional holdings, which can influence market perception and confidence.
• The disclosure of a substantial stake by a major asset manager may attract further institutional interest or reinforce existing investor positions.

Key Dates

Recommendation

The disclosure of a substantial 7.2% stake by FMR LLC, a prominent asset manager, indicates strong institutional confidence in Moderna's long-term value proposition. This significant holding by a sophisticated investor could be interpreted as a positive signal for other investors, suggesting a 'hold' recommendation for those aligned with long-term growth strategies in the biotechnology sector, or a 'buy' for those looking to initiate a position based on institutional conviction.

Keywords

Moderna, FMR LLC, Fidelity, Beneficial Ownership, Institutional Investor, mRNA, Biotechnology, Pharmaceuticals, MNA, Common Stock